Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Mehmet Asim Bilen"'
Autor:
Toni K. Choueiri, Amin Nassar, Pier Vitale Nuzzo, Marina D. Kaymakcalan, David A. Braun, Mehmet Asim Bilen, Sarah Abou-Alaiwi, Dylan J. Martini, John A. Steinharter, Ziad Bakouny, Justin H. Fleischer, Aly-Khan A. Lalani, Xiao X. Wei, Wanling Xie, Bradley Alexander McGregor, Lauren C. Harshman
Publikováno v:
European Journal of Cancer. 135:203-210
Background Cabozantinib is approved for the first and subsequent line treatment of metastatic clear-cell renal cell carcinoma (ccRCC) based on trials in which most patients were immune checkpoint blockade (ICB) naive. With an expanding role of ICB in
Autor:
Mehmet Asim Bilen, Yuan Liu, Sarah Caulfield, Julie M. Shabto, Bradley C. Carthon, Viraj A. Master, Wayne Harris, Omer Kucuk, Dylan J. Martini, Haydn T. Kissick, Greta Russler, Emilie Elise Hitron
Publikováno v:
The Oncologist
Background The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria are the gold standard for risk‐stratifying patients with metastatic renal cell cancer (mRCC). We developed a novel risk scoring system for patients wit
Autor:
Wanling Xie, Sumanta K. Pal, Daniel M. Geynisman, Elizabeth R. Plimack, Nieves Martinez Chanza, Jarred Burkart, Yousef Zakharia, Sumit A. Shah, Hannah Dzimitrowicz, Saby George, Mehmet Asim Bilen, Naomi B. Haas, Russell K. Pachynski, Walter M. Stadler, Dominick Bossé, I. Alex Bowman, Abhishek Tripathi, Lauren C. Harshman, Toni K. Choueiri, Nicholas J. Vogelzang, Sandy Srinivas, Andrew W. Hahn, Rana R. McKay, Anthony Mega, Benoit Beuselinck, Jo Ann Hsu, Vivek Narayan, Ulka N. Vaishampayan, Rohit Jain, Michael R. Harrison, Daniel Y.C. Heng, Neeraj Agarwal, Archana Balakrishnan, Benedito A. Carneiro, Amir Mortazavi, Hans J. Hammers, Elaine T. Lam, Tracy L. Rose
Publikováno v:
The Lancet Oncology. 20:581-590
Summary Background Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characteri
Autor:
Christopher P. Filson, Viraj A. Master, Thien-Linh Le, Mehmet Asim Bilen, Aaron H. Lay, Mehrdad Alemozaffar, Kenneth Ogan, John G. Pattaras, Dattatraya Patil, Kc Biebighauser Bens
Publikováno v:
Urology. 141
Objective To evaluate the relationship between dynamic changes in the modified Glasgow Prognostic Scale (mGPS) and postnephrectomy survival among localized clear cell renal cell carcinoma (ccRCC) patients. Methods We retrospectively identified patien
Autor:
Charles J. Ryan, Andrew Elliott, Benjamin A. Gartrell, Nancy A. Dawson, Shuanzeng Wei, Shuchi Gulati, Wolfgang Michael Korn, Matthew Zibelman, Arpit Rao, P.M. Coelho Barata, Elisabeth I. Heath, Earle F. Burgess, Tian Zhang, Kelsey Poorman, Rana R. McKay, Hans J. Hammers, Sourat Darabi, Mehmet Asim Bilen, Daniel M. Geynisman, Chadi Nabhan
Publikováno v:
Annals of Oncology. 32:S705
Autor:
Paul J. Catalano, Jeffrey A. Sosman, Naomi B. Haas, Robert S. Alter, David Peace, David F. McDermott, Jessica Hawley, Elizabeth R. Plimack, Sabina Signoretti, Opeyemi Jegede, Catherine J. Wu, Moshe Chaim Ornstein, Mehmet Asim Bilen, Michael B. Atkins, Hans J. Hammers, Michael E. Hurwitz
Publikováno v:
Journal of Clinical Oncology. 39:4510-4510
4510 Background: The HCRN GU16-260 trial reported on the efficacy and toxicity of nivo monotherapy in treatment naïve clear cell RCC (Cohort A) and the efficacy of nivo/ipi salvage therapy in pts with tumors resistant to initial nivo monotherapy (At
Autor:
Chung-Han Lee, Robert J. Motzer, Peter Kubiak, Alan D. Smith, Alvaro Pinto, Sara Gunnestad Ribe, Arpit Rao, Jane Wu, David R. Shaffer, James J. Hsieh, Christopher DiSimone, Allen Lee Cohn, Amishi Yogesh Shah, Regina Gironés Sarrió, Emmett V. Schmidt, Chinyere E. Okpara, Mehmet Asim Bilen
Publikováno v:
Journal of Clinical Oncology. 39:e16542-e16542
e16542 Background: Immune checkpoint inhibitors (ICIs) are commonly used as first-line treatment for pts with advanced RCC. In the recent phase 3 CLEAR trial, LEN + PEMBRO showed improved objective response rate (ORR), progression-free survival (PFS)
Autor:
Mehmet Asim Bilen, Hans J. Hammers, David F. McDermott, Wenxin Xu, Wanling Xie, Elisabeth I. Heath, Toni K. Choueiri, David A. Braun, Bradley Alexander McGregor, Praful Ravi, Rana R. McKay
Publikováno v:
Journal of Clinical Oncology. 39:TPS4592-TPS4592
TPS4592 Background: Despite advances in therapy of clear cell renal cell carcinoma, outcomes for patients with aRCCVH remain poor and these patients have typically been excluded from pivotal phase III studies. COSMIC-313 (NCT03937219) exploring C/N/I
Autor:
Aaron Lay, Mehrdad Alemozaffar, Kenneth Ogan, KC Biebighauser Bens, Viraj A. Master, Dattatraya Patil, Mehmet Asim Bilen, Christopher P. Filson, John G. Pattaras
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:The inflammation-based modified Glasgow Prognostic Score (mGPS) is widely used as a prognostic indicator before surgery; however, little information is available on its ...
Autor:
Chung-Han Lee, Arpit Rao, Sara Gunnestad Ribe, Allen Lee Cohn, James J. Hsieh, Jane Wu, Alan D. Smith, Mehmet Asim Bilen, David R. Shaffer, Robert J. Motzer, Alvaro Pinto, Amishi Yogesh Shah, Christopher Di Simone, Peter Kubiak, Emmett V. Schmidt, Rodolfo F. Perini, Regina Gironés Sarrió
Publikováno v:
Journal of Clinical Oncology. 38:5008-5008
5008 Background: LEN, a multikinase VEGFR inhibitor, plus everolimus is approved for advanced RCC after prior VEGF-targeted therapy. PEMBRO, an anti-PD-1 antibody, plus axitinib is approved as first-line therapy of advanced RCC. We report phase 2 res